Effects of a gonadotropin-releasing hormone agonist on progesterone formation in cultured human granulosa cells

Olsson, Jan‐Edvin; Åkesson, Ingegerd; Hillensjø, Torbjörn

doi:10.1530/acta.0.1220427

Cited by 19 publications

(6 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…It has been demonstrated that GnRH-I inhibited progesterone secretion in the rat and human ovary (Peng et al 1994, Olofsson et al 1995. However, other groups reported a stimulatory (Olsson et al 1990) or no effect (Casper et al 1984) of GnRH-I on progesterone production in hGLCs. Functionally, it has been shown that GnRH-II and GnRH-II agonist (10 −10 to 10 −7 M) inhibited basal and human chorionic gonadotrophin (hCG)-stimulated progesterone secretion in hGLCs, which were similar to the effects of GnRH-I treatment on ovarian steroidogenesis (Kang et al 2001a).…”

Section: Physiological Role Of Ovarian Gnrhs/ Gnrhrs In Granulosa-lutmentioning

confidence: 97%

Potential role of gonadotrophin-releasing hormone (GnRH)-I and GnRH-II in the ovary and ovarian cancer.

Kang

Choi²,

Yang³

et al. 2003

Endocrine-Related Cancer

View full text Add to dashboard Cite

Gonadotrophin-releasing hormone (GnRH) functions as a key neuroendocrine regulator of the hypothalamic-pituitary-gonadal axis. In addition to the hypothalamus and pituitary gland, GnRH and its receptor have been detected in other reproductive tissues including the gonads, placenta and tumours arising from these tissues. Recently, a second form of GnRH (GnRH-II) and type II GnRH receptor have been found in normal ovarian surface epithelium and neoplastic counterparts.

show abstract

Section: Physiological Role Of Ovarian Gnrhs/ Gnrhrs In Granulosa-lutmentioning

confidence: 97%

Potential role of gonadotrophin-releasing hormone (GnRH)-I and GnRH-II in the ovary and ovarian cancer.

Kang

Choi²,

Yang³

et al. 2003

Endocrine-Related Cancer

View full text Add to dashboard Cite

show abstract

“…This finding has been contested by two other groups (57,58). Recently Olsson and colleagues reported that a GnRH agonist at relatively high concentrations directly affects gonadotropin-stimulated progesterone formation of human granulosa cells and that these effects vary (inhibitory or stimulatory) according to the degree of follicular maturation (59).…”

Section: Direct Effects Of Gnrh Analogues On Human Ovarian Carcinomatamentioning

confidence: 99%

Intracellular actions of gonadotropic and peptide hormones and the therapeutic value of GnRH‐agonists in ovarian cancer

Emons¹,

Ortmann²,

Pahwa

et al. 1992

Acta Obstet Gynecol Scand

View full text Add to dashboard Cite

Acta Obstet Gynecol Scand 1992; 71 Suppl 155: 31-38 During the last two decades, considerable experimental evidence has been collected indicating that epithelial ovarian cancer might be gonadotropin dependent. LH and FSH receptors have been described in some of these tumors. The proliferation of ovarian cancer cells could be stimulated in vitro by gonadotropins. Suppression of endogenous LH and FSH secretion by GnRH-agonist treatment inhibited the growth of experimental or heterotransplanted ovarian cancers in various animal models. A number of recent phase II clinical trials have shown that the application of GnRH-agonists can lead to remission or stable disease in patients with relapsed advanced ovarian cancer. At present, prospective controlled clinical studies are being performed to assess the efficacy of GnRH-agonist treatment in addition to conventional surgical and cytostatic therapy in ovarian cancer in FIGO stages III and IV. Also, direct effects of GnRH analogues on ovarian cancer seem possible: a GnRH-like protein has been found in the human ovary. Our group discovered and partially characterized a specific GnRH-binding site (mol. wt 63.2 kDa) in ovarian cancer which is very similar to other human extrapituitary GnRHbinding sites of the low affinity, high capacity type, e.g. in breast cancer or the placenta. Recently, other groups have described also high affinity GnRH-agonist binding sites in ovarian cancer as well as in other extra pituitary tissues. First results from our laboratory indicate that the proliferation of certain ovarian cancer cell lines in vitro is reduced by both agonistic and antagonistic analogues of GnRH. Other authors were able to inhibit gonadotropin-induced in vitro proliferation of ovarian cancer cell lines by co-incubation with a GnRH-agonist. Thus GnRH -or a related compound -might act as an autocrine regulator of ovarian cancer proliferation, a finding which might be useful for the development of new therapeutic approaches.For more than a century it has been known that married women are much less likely to develop ovarian cancer (DC) than are unwed females (1). Some authors believed that this phenomenon was due to the suppression 'of the libido in unmarried women, causing hyperemia of the genital organs. Most gynecologists at that time, however, supposed that the higher incidence of DC in female celibates was caused by menstrual hyperemia, which occurred naturally more often in this population than in married women who had fewer menstruations due to pregnancies, child-bed and lactation (for review, see 2).Since the 1970s it has been shown by several investigators that the number of pregnancies and the duration of oral contraceptive use are significantly inversely related to the incidence of OC (e.g. 3-6). Fathalla (3) was the first to suggest that the incessant monthly ovulation which is characteristic of our species, in the 20th century at least, is a causal factor for the development of DC, due to the repeated rupture Acta Obstet Gynecol Scand Suppl J55

show abstract

“…In humans, GnRH-I was reported to exert inhibitory action on ovarian steroidogenesis, decreasing progesterone production. However, other studies reported either a stimulatory effect or an absence of any effect [30]. GnRH-II, similar to GnRH-I, inhibits progesterone secretion in human granulosa-luteal cells.…”

Section: Direct Effect Of Gnrh In the Ovarymentioning

confidence: 90%

Gonadotropin-Releasing Hormone Agonists in Fertility Preservation

Çakmak

Seli

2011

Fertility Preservation

View full text Add to dashboard Cite

Fertility preservation in females diagnosed with cancer has become an important area of investigation due to increasing cancer survival rates combined with delayed childbearing. Initial studies using gonadotropinreleasing hormone (GnRH) agonist cotreatment with chemotherapy demonstrated promising results for fertility preservation. If this protective effect of GnRH agonists is confirmed by the ongoing prospective randomized clinical trials, GnRH agonist cotreatment may become valuable option for fertility preservation in reproductive-age women undergoing chemotherapy. Thus, ovarian protection may enable the preservation of future fertility in survivors and, in addition, prevent other adverse effects of premature menopause, such as bone density loss, sexual dysfunction, and vasomotor symptoms. Keywords Gonadotropin-Releasing Hormone Agonists in Fertility PreservationHakan Cakmak and Emre Seli 13Cancer is not uncommon among younger women of reproductive age. More than 710,000 new female cancer cases were estimated to be diagnosed in 2009 in the USA [1]. Approximately 10% of female cancer cases occur under the age of 40 years [2]. Over the past three decades, there has been a remarkable improvement in the survival rates due to progress in cancer treatment. With improvements in treatment outcomes, 82% of women younger than 45 years diagnosed with cancer survived between 1999 and 2006 [2]. Moreover, it was previously estimated that by 2010, one in 250 adult women will be a cancer survivor [3]. As a consequence of the increase in the number of patients surviving cancer, greater attention has been focused on the effects of cancer treatment on the quality of life of the survivor.The treatment for most of the common cancer types in younger women involves either removal

show abstract

Effects of a gonadotropin-releasing hormone agonist on progesterone formation in cultured human granulosa cells

Cited by 19 publications

References 13 publications

Potential role of gonadotrophin-releasing hormone (GnRH)-I and GnRH-II in the ovary and ovarian cancer.

Potential role of gonadotrophin-releasing hormone (GnRH)-I and GnRH-II in the ovary and ovarian cancer.

Intracellular actions of gonadotropic and peptide hormones and the therapeutic value of GnRH‐agonists in ovarian cancer

Gonadotropin-Releasing Hormone Agonists in Fertility Preservation

Contact Info

Product

Resources

About